PT  - JOURNAL ARTICLE
AU  - Sikora, Marta
AU  - Skrzydlewski, Paweł
AU  - Perła-Kaján, Joanna
AU  - Jakubowski, Hieronim
TI  - Homocysteine thiolactone contributes to a prognostic value of fibrin clot structure/function in coronary artery disease patients
AID  - 10.1101/2022.07.12.22277430
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.12.22277430
4099  - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277430.short
4100  - http://medrxiv.org/content/early/2022/07/15/2022.07.12.22277430.full
AB  - Background Fibrin clot structure/function contributes to cardiovascular disease. We examined sulfur-containing metabolites as determinants of fibrin clot lysis time (CLT) and maximum absorbance (Absmax) in relation to outcomes in coronary artery disease (CAD) patients. Effects of B-vitamin/folate therapy on CLT and Absmax were studied.Methods and Findings Plasma samples were collected from 1,952 CAD patients randomized in a 2 × 2 factorial design to (i) folic acid, vitamins B12, B6; (ii) folic acid, vitamin B12; (iii) vitamin B6; (iv) placebo for 3.8 years in the Western Norway B-Vitamin Intervention Trial. Clot lysis time (CLT) and maximum absorbance (Absmax) were determined using a validated turbidimetric assay. Acute myocardial infarction (AMI) and mortality were assessed during a 7-year follow-up. Data were analyzed using bivariate and multiple regression. Survival free of events was studied using Kaplan Mayer plots. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models. Baseline urinary (u)Hcy-thiolactone and plasma Cys were significantly associated with CLT while plasma Hcy was significantly associated with Absmax, independently of fibrinogen, triglycerides, vitamin E, glomerular filtration rate, body mass index, age, sex plasma creatinine, CRP, HDL-C, ApoA1. B-vitamins/folate did not affect CLT and Absmax. Kaplan-Meier analysis showed associations of increased baseline CLT and Absmax with worse outcomes. In Cox regression analysis, baseline CLT and Absmax (>cutoff) predicted AMI (CLT: HR 1.58, 95% CI 1.10-2.28; P = 0.013. Absmax: HR 3.22, CI 1.19-8.69; P = 0.021) and mortality (CLT: HR 2.54, 95% CI 1.40-4.63; P = 0.002. Absmax: 2.39, 95% CI 1.17-4.92; P = 0.017). After adjustments for other prognostic biomarkers these associations remained significant.Conclusions uHcy-thiolactone and plasma Cys are novel determinants of CLT, an important predictor of adverse CAD outcomes. CLT and Absmax were not affected by B-vitamin/folate therapy, which could account for the lack of efficacy of such therapy in CAD.Trial Registration URL: http://clinicaltrials.gov. Identifier: NCT00354081Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00354081Funding StatementThis study was funded by grants from the National Science Center, Poland: 2016/23/B/NZ5/00573, 2018/29/B/NZ4/00771, 2019/33/B/NZ4/01760.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Regional Committee for Medical and Health Research Ethics, Bergen, Norway; by the Norwegian Medicines Agency, Bergen, Norway; and the WENBIT Steering Committee, Bergen, Norway.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript